Synchronized expressions of serum osteopontin and B cell–activating factor in autoimmune thyroid disease

Cheng, Chao‐Wen; Tang, Kuo‐Tung; Fang, Wen-Fang; Lin, Jiunn‐Diann

doi:10.1111/eci.13122

Cited by 7 publications

(6 citation statements)

References 41 publications

(91 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We recruited 84 patients with GD and 27 healthy donors (general clinical characteristics are summarized in Table 1 and Figure 1A) to evaluate BAFF expression. The results showed that the serum BAFF levels were significantly higher in GD patients than in healthy donors (Figure 1B), which is consistent with results reported in previous studies (14, 15, 22). To determine the factors related to BAFF overexpression, serum FT3, FT4, TRAb, TGAb, and TPOAb levels were measured, and the relationship between these data and BAFF was evaluated.…”

Section: Resultssupporting

confidence: 92%

Thyroid hormone induces B cells abnormal differentiation via overexpression of B cell-activating factor

Liu

et al. 2022

Preprint

View full text Add to dashboard Cite

Breakdown of tolerance and abnormal activation in B cells is an important mechanism in Graves’ disease (GD) pathogenesis. However, the mechanism by which B cells are abnormal differentiated and activated in GD remains elusive. Here, we show that elevated BAFF expression is positively correlated with serum thyroid hormone (TH) levels in GD patients and high TH levels can induce BAFF overexpression and lead to the abnormal differentiation of B cells in mice. This BAFF overexpression can be seen in many tissues. In the spleens of mice, high TH levels induce M1 macrophages polarization, which generates BAFF overexpression. Our findings open a new perspective on the interactions between endocrine and immune system and provide insight into the involvement of thyroid hormones in the development and progression of GD.

show abstract

Section: Resultssupporting

confidence: 92%

Thyroid hormone induces B cells abnormal differentiation via overexpression of B cell-activating factor

Liu

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…However, the association between thyroiditis and OPN is controversial. Cheng et al found no significant difference in OPN levels between inactive HT and normal controls and between active HT and controls, but they found higher serum OPN levels in active than in inactive Graves' disease and controls (Cheng et al, 2019). Due to this controversy, we excluded patients with thyroiditis findings in ultrasonographic evaluation from the study.…”

Section: Discussionmentioning

confidence: 96%

Serum osteopontin can improve papillary thyroid cancer risk assessment of Bethesda III thyroid nodules: a preliminary study

2021

View full text Add to dashboard Cite

Objective: Thyroid cancer can be detected in 5–10% of patients with thyroid nodules. Management may be a challenge if fine-needle aspiration biopsy yields Bethesda III findings. Most of these cases undergo surgery and are ultimately found benign. Our aim was to evaluate whether serum osteopontin can accurately estimate thyroid cancer risk in cases with cytologically Bethesda III thyroid nodules and, thereby, decrease the number of unnecessary surgical interventions. Design and Methods: We obtained blood samples of cases with repeated cytologically Bethesda III thyroid nodules before surgery, and followed up the pathology results after thyroidectomy. We evaluated serum osteopontin from 36 patients with papillary thyroid cancer and compared them with 40 benign cases. Results: Serum osteopontin levels in patients with papillary thyroid cancer are significantly higher than in benign cases (mean serum osteopontin: 10.48 ± 3.51 ng/mL vs 6.14 ± 2.29 ng/mL, p<0.001). The area under the receiver operating characteristics curve was 0.851, suggesting that serum osteopontin could have considerable discriminative performance. Conclusions: In our preliminary study, high serum osteopontin levels can predict the risk of papillary thyroid cancer in thyroid nodules with Bethesda III cytology. Further studies are necessary to confirm these findings.

show abstract

“…Either imbalanced BAFF or OPN can escape immune tolerance and result in AID development [ 45 – 50 ]. Moreover, in our recent publications, we demonstrated that serum BAFF and OPN levels were upregulated in GD, were associated with TSHRAb and thyroid function, and suggested that both BAFF and OPN could exhibit remarkable roles in inducing GD and modulating disease progression [ 51 , 52 ]. Correlations of KRT1 with BAFF and OPN levels indicate that the existence of KRT1 with either BAFF or OPN might be coordinated.…”

Section: Discussionmentioning

confidence: 99%

Associations of serum keratin 1 with thyroid function and immunity in Graves’ disease

Cheng,

Fang,

Lin

2023

PLoS ONE

Self Cite

View full text Add to dashboard Cite

Background Autoimmune thyroid disease (AITD) can cause enormous health burdens; however, trustworthy biomarkers in identifying the onset and progression of AITD are limited. In this study, we attempted to discover new potential serum biomarkers to discriminate AITD using mass spectrometry (MS). Methods In the biomarker study cohort, 20 patients with Graves’ disease (GD), 20 patients with Hashimoto’s thyroiditis (HT), and 20 healthy controls were enrolled for a liquid chromatographic-tandem MS assessment. A novel biomarker, keratin 1 (KRT1), was selected for further evaluation in the validation cohort, including 125 patients with GD, 34 patients with HT, and 77 controls. Relationships of serum KRT1 with AITD-related immunomodulatory cytokines were also analyzed using enzyme-linked immunosorbent assays (ELISAs). Results In the MS analysis, KRT1 was the single marker overexpressed in GD, while it was underexpressed in HT. In the ELISA analysis of the validation cohort, KRT1 was consistently upregulated in GD, while it was not downregulated in HT. There were significant associations of KRT1 levels with thyroid function in GD, AITD, and overall subjects. Additionally, a significant association of KRT1 levels with thyroid-stimulating hormone receptor antibody (TSHRAb) levels was observed. Moreover, there were significant associations of KRT1 with osteopontin (OPN) and B-cell activating factor (BAFF) levels in GD. Conclusions Serum KRT1 levels were upregulated in GD and were associated with thyroid function and TSHRAb levels. Moreover, KRT1 was correlated with the BAFF and OPN levels in GD patients. Further molecular-based research to elucidate the role of KRT1 in the pathogenesis of AITD is needed.

show abstract

Synchronized expressions of serum osteopontin and B cell–activating factor in autoimmune thyroid disease

Cited by 7 publications

References 41 publications

Thyroid hormone induces B cells abnormal differentiation via overexpression of B cell-activating factor

Thyroid hormone induces B cells abnormal differentiation via overexpression of B cell-activating factor

Serum osteopontin can improve papillary thyroid cancer risk assessment of Bethesda III thyroid nodules: a preliminary study

Associations of serum keratin 1 with thyroid function and immunity in Graves’ disease

Contact Info

Product

Resources

About